An Expanded Access Program of Carmeseal-MD (P-188 NF) outside of the United States

Trial Profile

An Expanded Access Program of Carmeseal-MD (P-188 NF) outside of the United States

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Heart failure
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 15 Sep 2017 New trial record
    • 13 Sep 2017 According to a Phrixus Pharmaceuticals media release, the company is about to treat first patient with Carmeseal-MD (P-188 NF) outside of the United States.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top